Atencion Farmaceutica al paciente VIH en tratamiento con Dolutegravir y Lamivudina

Perales Pascual, Judit; Navarro Aznarez, Herminia; López Pérez, Ana; Abad Bañuelos, Beatriz; Pascual Matínez, Oihana.
Pharm. care Esp ; 25(2): 22-33, 14-04-2023. tab
Artículo en Español | IBECS (España) | ID: ibc-219297

Documentos relacionados

  1. No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.
  2. Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence <i>In Vitro</i>.
  3. Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
  4. Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy.
  5. Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study.
  6. Preparation of a Key Intermediate En Route to the Anti-HIV Drug Lenacapavir.
  7. Lamivudine plus dolutegravir as a switch strategy in children: three case reports.
  8. Strategies for an HIV cure: progress and challenges.
  9. Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
  10. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.